Molecular dan Genomic Biomarker sebagai Deteksi Dini pada Diagnosis Kanker Prostat

Jihan Audini Karim


Prostate cancer is a noncutaneous malignancy in men, a heterogeneous disease with varying clinical outcomes. The modern clinical approach to prostate cancer emphasizes the need for treatment to avoid overdiagnosis and overtreatment. Advances in understanding of the pathogenesis of prostate cancer, coupled with technological innovations, have facilitated the development and validation of a number of molecular biomarkers, representing a variety of tested macromolecules from a wide variety of patient samples, to aid clinical management of prostate cancer, including early detection, diagnosis, prognostication, and selection. targeted therapy. Prostate cancer is asymptomatic in the early stages of the disease, there are various clinical-pathological signs and disease progression, and is characterized mostly by indolent cancer types. Therefore, it is imperative to develop individualized approaches for early detection, disease stratification (indolent vs. aggressive) and prediction of treatment response for prostate cancer. This article is a review article in which researchers review the current state of use of genomic biomarkers for early detection of prostate cancer, demonstrating the function of molecular biomarkers in clinical practice. The result of this review article is that the available genomic and proteomic tests can increase the predictive value of the PCa risk classification system based on clinical variables.


Biomarker; Molecular; Kanker; Prostat

Full Text:



Aubin MJ, Reid J, Sarno MJ, Blasé A., Aussie J, Rittenhouse H, Groskopf J, 2010. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: Validation in the placebo arm of the dutasteride REDUCE trial. Journal of Urology. 184(5): 1947-1952.

Barbera M, Pepe P, Paola Q, & Aragona F, 2012. PCA3 score accuracy in diagnosing prostate cancer at repeat biopsy: Our experience in 177 patients. Archivio Italiano Di Urologia e Andrologia. 84(4): 227-229.

Barry MJ and Hayes JH, 2015. Evaluating an elevated screening PSA Test. Journal of the American Medical Association. 314(19): 2073-2074.

Bidarra D, Constâncio V, Barros-Silva D, Ramalho-Carvalho J, Moreira-Barbosa C, et al, 2019. Circulating MicroRNAs as Biomarkers for Prostate Cancer Detection and Metastasis Development Prediction. Frontiers in Oncology. 9: 1-8.

Bourdoumis A, Papatsoris AG, Chrisofos M, Efstathiou E, Skolarikos A, & Deliveliotis C, 2010. The novel prostate cancer antigen 3 (PCA3) biomarker. International Braz J Urol. 36(6): 665-668.

Cazares LH, Drake RR, Esquela-Kirscher A, Lance RS, Semmes OJ, and Troyer DA, 2011. Molecular pathology of prostate cancer. Cancer Biomarkers. 9(1-6): 441-459.

Chen S, Tauber G, Langsenlehner T, Schmölzer LM, Pötscher M, Riethdorf S, El-Heliebi A, 2019. In Vivo detection of circulating tumor cells in High-Risk Non-Metastatic Prostate Cancer Patients undergoing Radiotherapy. Cancers (Basel). 11(7): 933.

Coumans FAW, Ligthart ST, Uhr JW & Terstappen LWMM, 2012. Challenges in the enumeration and phenotyping of CTC. Clinical Cancer Research. 18(20): 5711-5718.

Ding Y, Wu H, Warden C, Steele L, Liu X, van Iterson M, Neuhausen SL, 2016. Gene Expression Differences in Prostate Cancers between Young and Old Men. PLoS Genetics. 12(12): e1006477.

Feigin VL, Krishnamurthi RV, Theadom AM, Abajobir AA, Mishra SR, Ahmed MB, Zaki ME, 2017. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet Neurology. 16(11): 877-897.

Fujita K, and Nonomura N, 2019. Role of Androgen Receptor in Prostate Cancer: A Review. The World Journal of Men’s Health. 37(3): 288-295.

Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Vogelzang NJ, 2014. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: A phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. Journal of Clinical Oncology. 32(11): 1136-1142.

Gottlieb B, Beitel LK, Nadarajah A, Paliouras M, and Trifiro M, 2012. The Androgen Receptor Gene Mutations Database: 2012 Update. Human Mutation. 33(5): 887-894.

Hong B, and Zu Y, 2013. Detecting circulating tumor cells: Current challenges and new trends. Theranostics. 3(6): 377-394.

Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, and Lotan TL, 2018. Clinical Implications of PTEN Loss in Prostate Cancer. Nature Reviews Urology. 15(4): 222-234.

Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, and Isaacs WB, 2015. Understanding The Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at The Molecular Level. European Urology. 67(3): 470-479.

Kissick HT, On ST, Dunn LK, Sanda MG, Asara JM, Pellegrini KL, Arredouani MS, 2015. The Transcription Factor ERG Increases Expression of Neurotransmitter Receptors on Prostate Cancer Cells. BMC Cancer. 15: 604.

Kojima S, Goto Y, and Naya Y, 2017. The Roles of Micrornas in the Progression of Castration-Resistant Prostate Cancer. Journal of Human Genetics. 62: 25-31.

Kulda V, Topolcan O, Kucera R, Kripnerova M, Srbecka K, et al, 2016. Prognostic Significance of Tmprss2-Erg Fusion Gene in Prostate Cancer. Anticancer Research. 36(9): 4787-4793.

Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, et al, 2011. PTEN Protein Loss By Immunostaining: Analytic Validation and Prognostic Indicator for A High Risk Surgical Cohort of Prostate Cancer Patients. Clinical Cancer Research. 17(20): 6563-6573.

Malinowski B, Wiciński M, Musiała N, Osowska I, and Szostak M, 2019. Previous, Current, and Future Pharmacotherapy and Diagnosis of Prostate Cancer-A Comprehensive Review. Diagnostics (Basel). 9(4): 161.

Matin F, Jeet V, Moya L, Selth LA, Chambers S, Clements JA, Kerr K, 2018. A Plasma Biomarker Panel of Four MicroRNAs for The Diagnosis of Prostate Cancer. Scientific Reports. 8: 6653.

Mohler JL, Armstrong AJ, Bahnson RR, D’Amico AV, Davis BJ, Eastham JA, Freedman-Cass DA, 2016. Prostate Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network. 14(1): 19-30.

Saucedo-Zeni N, Mewes S, Niestroj R, Gasiorowski L, Murawa D, et al, 2012. A Novel Method for the in Vivo Isolation of Circulating Tumor Cells from Peripheral Blood Of Cancer Patients Using a Functionalized and Structured Medical Wire. International Journal of Oncology. 41(4): 1241-1250.

Schleutker J, 2012. Polymorphisms in Androgen Signaling Pathway Predisposing to Prostate Cancer. Molecular and Cellularssss Endocrinology. 360(1-2): 25-37.

Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe L, et al, 2014. Enzalutamide in Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel and Abiraterone. European Urology. 65(1): 30-36.

Song MS, Salmena L, and Pandolfi PP, 2012. The Functions and Regulation of The PTEN Tumour Suppressor. Nature Reviews Molecular Cell Biology. 13: 283-296.

Steinestel J, Luedeke M, Arndt A, Schnoeller TJ, Lennerz JK, et al, 2019. Detecting Predictive Androgen Receptor Modifications in Circulating Prostate Cancer Cells. Oncotarget. 10(41): 4213-4223.

Tandefelt DG, Boormans J, Hermans K, and Trapman J, 2014. ETS Fusion Genes in Prostate Cancer. Endocrine-Related Cancer. 21(3): R143-152.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, and Jemal A, 2015. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians. 65(2): 87-108.

Wang Z, Wang Y, Zhang J, Hu Q, Zhi F, et al, 2017. Significance of the TMPRSS2: ERG Gene Fusion in Prostate Cancer. Molecular Medicine Reports. 16(4): 5450-5458.

Yoo S, Pettersson A, Jordahl KM, Lis RT, Lindstrom S, et al, 2014. Androgen Receptor CAG Repeat Polymorphism and Risk of TMPRSS2: ERG-Positive Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention. 23(10): 2027-2031.

Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, et al, 2010. An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression. Cancer Cell. 17(5): 443-454.

Yu M, Stott S, Toner M, Maheswaran S, and Haber DA, 2011. Circulating Tumor Cells: Approaches to Isolation and Characterization. Journal of Cell Biology. 192(3): 373-382.



  • There are currently no refbacks.

Copyright (c) 2020 Jihan Audini Karim

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.



Jurnal Ilmiah Kedokteran Wijaya Kusuma 

ISSN: 1978-2071(print); 2580-5967 (online)
Published by the Institute for Research and Community Services (LPPM) of University of Wijaya Kusuma Surabaya.
Surabaya, Indonesia
Creative Commons License
All publications by Jurnal Ilmiah Kedokteran Wijaya Kusuma are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
counter View My Stats